Dir
Christopher Gibson (often referred to as Chris Gibson), Ph.D., is the co-founder, former CEO, and current Board Chair and Director of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical-stage TechBio company using automation, AI, biology, and chemistry to industrialize drug discovery.[[1]](https://www.aspenideas.org/speakers/christopher-gibson)[[4]](https://www.recursion.com/team-members/chris-gibson) He recently sold 40,000 shares of Class A Common Stock on January 5, 2026, at $4.25 per share, totaling $170,000, under a Rule 10b5-1 trading plan, and converted additional Class B shares, retaining significant direct and indirect ownership.[[5]](https://www.investing.com/news/insider-trading-news/recursion-pharma-director-gibson-sells-170k-in-shares-93CH-4436118)
Gibson earned undergraduate degrees in bioengineering and managerial studies, completed an entrepreneurship course at Stanford Graduate School of Business, and obtained his PhD from the University of Utah in 2013 under co-founder Dean Li, during which he developed Recursion's core technology.[[1]](https://www.aspenideas.org/speakers/christopher-gibson)[[4]](https://www.recursion.com/team-members/chris-gibson) He founded Recursion in 2013, served as CEO until December 2025—growing it from a startup to a public company with over 600 employees, landmark partnerships (e.g., Roche/Genentech, Sanofi, Bayer), one of the world's largest biological/chemical datasets, and an in-house supercomputer—before transitioning to Chairman effective January 1, 2026, with Najat Khan succeeding as CEO.[[2]](https://www.statnews.com/2025/11/05/recursion-ceo-chris-gibson-out-najat-khan-new-head/)[[3]](https://www.biocentury.com/article/657497/recursion-picks-j-j-alum-khan-to-succeed-gibson-as-ceo)[[4]](https://www.recursion.com/team-members/chris-gibson) He serves on the board of CureHHT and the Rare and Undiagnosed Network Advisory Board.[[1]](https://www.aspenideas.org/speakers/christopher-gibson)
View full insider profile →
